Aging of rat heart myocytes disrupts muscarinic receptor coupling that leads to inhibition of cAMP accumulation and alters the pathway of muscarinic-stimulated phosphoinositide hydrolysis.
The biochemical responses to muscarinic stimulation (inhibition of isoproterenol-stimulated cAMP accumulation and stimulation of phosphoinositide turnover) were investigated in intact myocyte cultures prepared from the hearts of newborn rats. The studies employed young (5 days after plating) and aged (14 days old) myocyte cultures. Aging of the myocyte cultures was accompanied by marked alterations in both the inhibition of cAMP accumulation and the stimulation of the phosphoinositide metabolism via the muscarinic receptors. However, the effects on the two muscarinic responses were different. The first response was disrupted at the level of the coupling of the muscarinic receptors with adenylate cyclase through Gi. On the other hand, muscarinic stimulation of phosphoinositide hydrolysis still occurred in the aged myocyte cultures; however, the inositol trisphosphate generated was not converted to inositol 1-phosphate as in young cultures or as in aged cultures stimulated by norepinephrine. This raises the possibility that muscarinic activation of aged myocyte cultures shifts the metabolic state of the cells and alters the pathway of phosphoinositide hydrolysis. Treatment of aging cultures with phosphatidylcholine liposomes under conditions that yielded aged myocyte cultures with a lipid composition resembling that of young ones restored the muscarinic effect on cAMP accumulation, where the impairment in aged cultures was at the coupling stage (which takes place in the plasma membrane). This treatment had no effect on the response of the phosphoinositide metabolism to muscarinic stimulation.
Moscona-Amir
E
E
Department of Biochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
Henis
Y I
YI
Sokolovsky
M
M
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001667:Binding, Competitive; D002217:Carbachol / Q000378:metabolism / Q000494:pharmacology; D002478:Cells, Cultured; D002772:Cholera Toxin / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology*; D007700:Kinetics; D009206:Myocardium / Q000378:metabolism*; D009638:Norepinephrine / Q000494:pharmacology; D010095:Oxotremorine / Q000378:metabolism / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism; D051381:Rats; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors
D010716:Phosphatidylinositols; D011976:Receptors, Muscarinic; D005576:Colforsin; D015124:8-Bromo Cyclic Adenosine Monophosphate; D010095:Oxotremorine; D002217:Carbachol; D002772:Cholera Toxin; D000242:Cyclic AMP; D007545:Isoproterenol; D015056:1-Methyl-3-isobutylxanthine; D009638:Norepinephrine